Michelle Chen

President & CEO at Form Bio

Speaker

Michelle Chen, Ph.D. is a biotech C-level executive and industry leader with extensive experience in AI strategy, business and corporate development, M&A, investor relations, ventures, fundraising, and R&D. She currently serves as President, CEO and Board Member of Form Bio, the first spin-off from Colossal Biosciences, where she leads company’s efforts to harness AI for genetic medicine design, development and genome engineering applications.

Prior to Form Bio, Michelle served as Chief Business Officer at Insilico Medicine which went IPO on the Hong Kong Stock Exchange on December 30, 2025 (market cap > USD $4B as of Jan 28, 2026). During her four years there, she led the company’s business growth by translating cutting-edge AI technologies into high-value drug discovery and platform partnerships—unlocking billions in potential revenue.

Throughout her career, Michelle has built a strong cross-functional track record spanning R&D, product management, operations, and commercial leadership. She has held key positions at Roche, Merck, BioMarin, and Agilent Technologies, and has also served as an advisor to venture capital firms and startups. Michelle has led new company formations, executed numerous M&A transactions across the U.S., Europe, and Asia, and helped deliver a five-fold increase in the market capitalization of a public company within three years.

Michelle earned her Ph.D. in Biochemistry from the University of Washington, conducted postdoctoral research at UC San Francisco, and completed Bioinformatics training at Stanford University.